RJA
SNNA

Raymond James & Associates’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Raymond James & Associates’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,226
Closed -$5K – 3801
2019
Q3 		$5K Hold
23,226
– – ﹤0.01% 3582
2019
Q2 		$20K Hold
23,226
– – ﹤0.01% 3558
2019
Q1 		$54K Hold
23,226
– – ﹤0.01% 3471
2018
Q4 		$54K Buy
+23,226
New +$205K ﹤0.01% 3377

Other funds holding SNNA

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PO
Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Raymond James & Associates's SNNA Position: Q4 2019 in Review

Raymond James & Associates sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 23,226 shares — an estimated $5K sold.

Raymond James & Associates first reported a position in SNNA in Q4 2018 and held it in 4 quarters. The position peaked at $54K in Q1 2019. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

  • Raymond James & Associates reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Raymond James & Associates sold 23,226 Sienna Biopharmaceuticals, Inc. shares in Q4 2019, an estimated $5K.
  • Raymond James & Associates first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2018 and held it in 4 quarters.
  • Raymond James & Associates's Sienna Biopharmaceuticals, Inc. position peaked at $54K in Q1 2019.
  • 4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on Raymond James & Associates's 13F filing for Q4 2019, filed 12 Feb 2020.